Anteris Technologies Global Corp. (AVR)
NGM · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Anteris Technologies Global Corp.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 429K | 310K | 494K | 1.0M |
| Gross Profit | 306K | 219K | 380K | 776K |
| Operating Income | (22.3M) | (29.2M) | (24.0M) | (31.0M) |
| Net Income | (22.2M) | (29.2M) | (23.0M) | (29.1M) |
| Diluted EPS | $-0.62 | N/A | $-0.28 | $-0.30 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.2M | 2.7M | ||
| Gross Profit | 298K | 877K | ||
| Operating Income | (31.5M) | (46.7M) | ||
| Net Income | (30.6M) | (46.0M) | ||
| Diluted EPS | $-2.26 | $-2.94 | $-3.77 | $-2.55 |